Navigation Links
Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
Date:10/7/2010

ical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel, rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a second novel, rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial and data analysis timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
3. Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery
4. FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D.
5. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
6. Michael W. Marine Appointed CEO of Sabin Vaccine Institute
7. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
8. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
9. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
10. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
11. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Reportlinker.com announces that ... its catalogue: Antibody Drug Conjugates Market ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION Antibody ... therapeutic agents, gaining increasing attention from both large ... marriage of an antibody with a toxic drug ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... , TUCSON, Ariz. , Feb. 4 ... care. Arizona Oncology physicians will now treat patients at Marana Healthcare Clinic ... medical oncologists, are now actively caring for patients at MHC. , "We ... "By providing cancer care services in Marana we are able ...
... , SUNNYVALE, Calif. , Feb. 4 ... of radiosurgery, announced today financial results for the second quarter of fiscal ... second quarter of fiscal 2010, Accuray reported total revenue of $57.3 ... of $57.6 million . , Accuray reported a net loss ...
Cached Medicine Technology:Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 2Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 3Cancer Patients in Marana Now Have Local Access to Advanced Cancer Care 4Accuray Announces Results for Second Quarter Fiscal 2010 2Accuray Announces Results for Second Quarter Fiscal 2010 3Accuray Announces Results for Second Quarter Fiscal 2010 4Accuray Announces Results for Second Quarter Fiscal 2010 5Accuray Announces Results for Second Quarter Fiscal 2010 6Accuray Announces Results for Second Quarter Fiscal 2010 7Accuray Announces Results for Second Quarter Fiscal 2010 8Accuray Announces Results for Second Quarter Fiscal 2010 9Accuray Announces Results for Second Quarter Fiscal 2010 10Accuray Announces Results for Second Quarter Fiscal 2010 11Accuray Announces Results for Second Quarter Fiscal 2010 12
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
... the largest study of its kind for the genetic roots ... Disease as well as further evidence that some people of ... study examined changes in DNA associated with the two most ... which is most frequently marked by inflammation of the final ...
... Assessment Tools To ... Healthier Lifestyles, NEW YORK, March 26 EnergyNow!, ... and fitness,technology fields, today announced the availability of a ... Delaware, Maryland,Pennsylvania, Virginia, West Virginia and Washington D.C. combat ...
... Governor Edward G.,Rendell today announced the state,s new ... ahead to better meet their future,long-term care needs., ... be put off. If,people do fail to prepare, it ... "The ,Own Your Future, campaign,empowers consumers to take steps ...
... Award-Winning Mind Fitness Company, WASHINGTON, March 26 ... Ltd., the company that uses the latest scientific,research ... cognitive,performance and health, today announced that it will ... the American Society on Aging,(ASA), as a consultant., ...
... Technologies(R),Inc. ("Global Med" or the "Company") (OTC Bulletin ... announced,the sale yesterday, March 25, 2008, of approximately ... was held by SingXpress Ltd., an Asian company,(previously ... were sold,to five American institutions and the transaction ...
... lower health-related quality of life for their children ... from the parents of healthy children. However, reports ... These findings are published in the April issue ... online at Wiley Interscience (www.interscience.wiley.com ). , Children ...
Cached Medicine News:Health News:Large multicenter study suggests new genetic markers for Crohn's disease 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 3Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Global Med Technologies(R), Inc. Announces the Sale of Approximately 3.3 Million Shares of Global Med Common Stock Held by SingXpress Ltd., an Asian Company, to Five American Institutions 2Health News:Study shows lifetime effects of pediatric liver transplants 2
... Lyphochek Immunoassay Plus Control provides ... comprehensive control in the world for ... procedures, eliminating the need for separate ... no added preservatives, it is suitable ...
... Plus Control is a liquid ... today's busy immunoassay laboratory. With ... human serum based control can ... control products for immunoassay and ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Detection Platform provides fully automated detection of ... platform for molecular pathology labs separates DNA ... features that deliver a high degree of ... the capacity to run two 96-well plates, ...
Medicine Products: